NCT05040217
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
Active, Not Recruiting
PHASE1Ages 50–80InterventionalTreatmentMark TuszynskiInvestigator-initiated
~12 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:AAV2-BDNF Gene Therapy
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety as assessed by mumber of participants with treatment-related adverse events assessed on MRI scan
Measured over 24 months
+2 more outcomes measured
Conditions
Where it's being run
2 sites across 2 statesCalifornia1
Ohio1
Study leadership
- Mark Tuszynski, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Safety as assessed by mumber of participants with treatment-related adverse events assessed on MRI scan24 months
Number of participants with treatment-related adverse events assessed on MRI scan
- Memory change tested on Ray Auditory Verbal Learning Task24 months
Memory tested on Ray Auditory Verbal Learning Task
- Memory change tested on Benson Complex Figure Draw and Memory24 months
Memory tested on Benson Complex Figure Draw and Memory